Renovacor, Inc. – AMEX:RCOR

Renovacor stock price today

$3.2
+3.2

Renovacor stock price monthly change

-100.00%
month

Renovacor stock price quarterly change

-100.00%
quarter

Renovacor key metrics

Market Cap
 N/A
Enterprise value
 2.73M
P/E
 -6.75
EV/Sales
 N/A
EV/EBITDA
 -0.14
Price/Sales
 N/A
Price/Book
 1.30
PEG ratio
 0.01
EPS
 N/A
Revenue
 N/A
EBITDA
 N/A
Income
 N/A
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Renovacor stock price history

Renovacor stock forecast

Renovacor financial statements

Quarterly Earnings

Renovacor, Inc. (AMEX:RCOR): Earnings per share (EPS)
2022-05-12 -0.39 0.36
2022-08-08 -0.6 -0.23
2022-12-01 -0.53 -0.87
RCOR earnings history

Renovacor alternative data

Renovacor
Employees

Renovacor, Inc. (AMEX:RCOR): Employee count
Aug 2023 19
Sep 2023 19
Oct 2023 19
Nov 2023 19
Dec 2023 19
Jan 2024 19
Feb 2024 19
Mar 2024 19
Apr 2024 19
May 2024 19
Jun 2024 19
Jul 2024 19
Dec 2024 19

Renovacor other data

Renovacor
Insider Trading

Renovacor, Inc. (AMEX:RCOR): Insider trades (number of shares)
Period Buy Sel
Sep 2021 800000 0
Nov 2021 250000 0
Dec 2021 210000 0
Jan 2022 349334 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
RTW INVESTMENTS, LP 10 percent owner
 Common Stock, par value $0.0001 per share ("Common Stock") 44,440 $8 $355,520
Purchase
RTW INVESTMENTS, LP 10 percent owner
 Common Stock 5,723 $8 $45,784
Purchase
RTW INVESTMENTS, LP 10 percent owner
 Common Stock 145,000 $8 $1,159,710
Purchase
RTW INVESTMENTS, LP 10 percent owner
 Common Stock 286 $7.75 $2,217
Purchase
RTW INVESTMENTS, LP 10 percent owner
 Common Stock, par value $0.0001 per share ("Common Stock") 1,950 $7.67 $14,957
Purchase
RTW INVESTMENTS, LP 10 percent owner
 Common Stock 51,296 $8 $410,368
Purchase
RTW INVESTMENTS, LP 10 percent owner
 Common Stock 100,195 $8 $801,560
Purchase
RTW INVESTMENTS, LP 10 percent owner
 Common Stock, par value $0.0001 per share ("Common Stock") 3 $8 $24
Purchase
RTW INVESTMENTS, LP 10 percent owner
 Common Stock 441 $7.95 $3,506
Purchase
RTW INVESTMENTS, LP 10 percent owner
 Common Stock 3,743 $8 $29,944
RCOR insider trading transactions

Frequently Asked Questions (FAQ)

  • What's the price of Renovacor stock today?

    One share of Renovacor stock can currently be purchased for approximately $3.2.

  • When is Renovacor's next earnings date?

    Unfortunately, Renovacor's (RCOR) next earnings date is currently unknown.

  • Does Renovacor pay dividends?

    No, Renovacor does not pay dividends.

  • What is Renovacor's stock symbol?

    Renovacor, Inc. is traded on the AMEX under the ticker symbol "RCOR".

  • What is Renovacor's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Renovacor?

    Shares of Renovacor can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Renovacor have?

    As Dec 2024, Renovacor employs 19 workers.

  • When Renovacor went public?

    Renovacor, Inc. is publicly traded company for more then 5 years since IPO on 22 Jun 2020.

  • What is Renovacor's official website?

    The official website for Renovacor is renovacor.com.

  • Where are Renovacor's headquarters?

    Renovacor is headquartered at PO Box 8142, Greenwich, CT.

  • How can i contact Renovacor?

    Renovacor's mailing address is PO Box 8142, Greenwich, CT and company can be reached via phone at +61 4242650.

Renovacor company profile:

Renovacor, Inc.

renovacor.com
Exchange:

AMEX

Full time employees:

19

Industry:

Biotechnology

Sector:

Healthcare

Renovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut.

+61 4242650
PO Box 8142
Greenwich, CT 06836

CIK: 0001799850
ISIN: US75989E1064
CUSIP: 75989E106